Skip to main content
SpringerLink
Log in

The Role of Systemic Chemotherapy in the Treatment of Kidney Cancer

  • Chapter
Book cover Kidney Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 116))

Abstract

The prognosis for patients with metastatic renal cell carcinoma (RCC) is poor. The median overall survival time of patients with advanced disease is approximately 10 months with a 3-year survival rate of about 10%1. RCC is typically described as chemotherapy (and radiation therapy) resistant. Most authors agree that biologic response modifiers (i e immunotherapy) represent standard first-line treatment for advanced RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530–2540,1999.

    PubMed  CAS  Google Scholar 

  2. Vogelzang NJ, Priest ER, Borden L Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 148: 1247–1248,1992.

    PubMed  CAS  Google Scholar 

  3. Motzer RJ, Russo P Systemic therapy for renal cell carcinoma. J Urol 163: 408–417,2000.

    Article  PubMed  CAS  Google Scholar 

  4. Oliver RT, Nethersell AB, Bottomley N. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 63: 128–131,1989.

    Article  PubMed  CAS  Google Scholar 

  5. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-lb compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338: 1265–1271,1998.

    Article  PubMed  CAS  Google Scholar 

  6. Hrushesky WJ, Murphy GP. Current status of the therapy of advanced renal carcinoma. J Surg Oncol 9: 277–288,1977.

    Article  PubMed  CAS  Google Scholar 

  7. Henriksson R, Nilsson G, Colleen S. Survival in renal cell carcinoma—a randomized evaluation of tamoxifen vs. interleukin-2, alpha-interferon (leucocyte) and tamoxifen. Br J Cancer 77: 1211,1998.

    Article  Google Scholar 

  8. Gershanovich MM, Gorelov AI, Hajba A, et al. High-dose toremifene (HDT) for the treatment of locally advanced and metastatic renal cell carcinoma. Proc Amer Soc of Clin Oncol 21:19a (abstract 757): 757, 2002.

    Google Scholar 

  9. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 27: 177–186, 2000.

    PubMed  CAS  Google Scholar 

  10. Harris DT. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 10: 422–430, 1983.

    PubMed  CAS  Google Scholar 

  11. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 22: 42–60, 1995.

    PubMed  CAS  Google Scholar 

  12. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 20: 303–321, 1993.

    PubMed  CAS  Google Scholar 

  13. Kuebler JP, Hogan TF, Trump DL, et al. Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma. Cancer Treat Rep 68: 925–926, 1984.

    PubMed  CAS  Google Scholar 

  14. Fossa SD, Droz JP, Pavone-Macaluso MM, et al. Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur J Cancer: 878–880, 1992.

    Google Scholar 

  15. Zeffren J, Yagoda A, Kelsen D, et al. Phase I-II trial of a 5-day continuous infusion of vinblastine sulfate. Anticancer Res 4: 411–413, 1984.

    PubMed  CAS  Google Scholar 

  16. Tannock IF, Evans WK. Failure of 5-day vinblastine infusion in the treatment of patients with renal cell carcinoma. Cancer Treat Rep 69: 227–228, 1985.

    PubMed  CAS  Google Scholar 

  17. Crivellari D, Tumolo S, Frustaci S, et al. Phase II study of five-day continuous infusion of vinblastine in patients with metastatic renal-cell carcinoma. Am j Clin Oncol 10: 231–233, 1987.

    Article  PubMed  CAS  Google Scholar 

  18. Elson PJ, Kvols LK, Vogl SE, et al. Phase II trials of 5-day vinblastine infusion (NSC 49842), Lalanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. Invest New Drugs 6: 97–103, 1988.

    Article  PubMed  CAS  Google Scholar 

  19. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859–2867, 1999.

    PubMed  CAS  Google Scholar 

  20. Kish JA, Wolf M, Crawford ED, et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer 74: 916–919, 1994.

    Article  PubMed  CAS  Google Scholar 

  21. Hrushesky WI von Roemeling R, Lanning RM, et al. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 8: 1504–1513, 1990.

    PubMed  CAS  Google Scholar 

  22. Dexeus FH, Logothetis CJ, Sella A, et al Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. j Urol 146: 709–713, 1991.

    PubMed  CAS  Google Scholar 

  23. Damascelli B, Marchiano A, Spreafico C, et al Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. Cancer 66: 237–241, 1990.

    Article  PubMed  CAS  Google Scholar 

  24. Merrouche Y, Negrier S, FL, et al. Phase II study of continous circadian infusion FUDR in metastatic renal cell cancer (RCC). Eur J Cancer Clin Oncol 27: 1991.

    Google Scholar 

  25. Dimopoulous MA, Dexeus FH, Jones E, et al. Evidence for additive anti-tumor activity and toxicity for the combination of FUDR and interferon alpha2B in patients (pts) with metastatic renal cell carcinoma (RCC). Proc Am Assoc Cancer Res 32: 186, 1991.

    Google Scholar 

  26. Richards F, Cooper MR, Jackson DV, et al. Continuous 5-day (D) intravenous (IV) FUDR infusion for renal cell carcinoma (RCC): A phase I-II trial of the Piedmont Oncology Association. Proc Am Soc Clin Oncol 10: 170, 1991.

    Google Scholar 

  27. Budd GT, Murthy S, Klein E, et al. Time-modified infusion of floxuridine in metastatic renal cell carcinoma (mRCC). Proc Am Assoc Cancer Res 33: 220, 1992.

    Google Scholar 

  28. Conroy T, Geoffrois L, Guillemin F, et al. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma. Cancer 72: 2190–2197, 1993.

    Article  PubMed  CAS  Google Scholar 

  29. Weissbach L, de Mulder P, Osieka R, et al. Phase II study of gemcitabine in renal cancer. Proc Am Soc Clin Oncol 11: 219, 1992.

    Google Scholar 

  30. Mertens WC, Eisenhauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 4: 331–332, 1993.

    PubMed  CAS  Google Scholar 

  31. Moore MJ, CM K, Ernst S. A phase II study of troxacitabine in patients with advanced and/or metastatic renal cell carcinoma. NCIC CTG IND.119. Proc Am Soc of Clin Oncol 20:193a (abstract 768): 2001.

    Google Scholar 

  32. Dana BW, Alberts DS. Combination chemoimmunotherapy for advanced renal carcinoma with Adriamycin, bleomycin, vincristine, cyclophosphamide, plus BCG. Cancer Clin Trials 4: 205–207, 1981.

    PubMed  CAS  Google Scholar 

  33. Droz.Th Theodore C, Ghosn M, et al. Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-Roussy. Semin Surg Oncol 4: 97–99,1988.

    PubMed  CAS  Google Scholar 

  34. Wada T, Houjou T, Kubo R, et al. A combined chemo-endocrine treatment with tegafur, adriamycin, methotrexate and tamoxifen for advanced renal cell carcinoma. Anticancer Res 13: 2465— 2467,1993.

    PubMed  CAS  Google Scholar 

  35. Katakkar SB, Franks CR. Chemo-hormonal therapy for metastatic renal cell carcinoma with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate. Cancer Treat Rep 62: 1379— 1380,1978.

    Google Scholar 

  36. Jekunen A, Stengard J, Pyrhonen S. Phase II study of vinblastine and doxorubicin in advanced renal cell carcinoma. Eur J Cancer 2: 245,1994.

    Article  Google Scholar 

  37. Sommer HH Fossa SD, Lien HH. Combination chemotherapy of advanced renal cell cancer with CCNU and vinblastine. Cancer Chemother Pharmacol 14: 277–278,1985.

    Article  PubMed  CAS  Google Scholar 

  38. Merrin C, Mittelman A, Fanous N, et al. Chemotherapy of advanced renal cell carcinoma with vinblastine and CCNU. J Urol 113: 21–23,1975.

    PubMed  CAS  Google Scholar 

  39. Hahn RG, Temkin NR, Savlov ED, et al. Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer. Cancer Treat Rep 62: 1093–1095,1978.

    PubMed  CAS  Google Scholar 

  40. Rini BI, Vogelzang NJ, Dumas MC, et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18: 2419–2426,2000.

    PubMed  CAS  Google Scholar 

  41. George GM, Dezheng H, Vogelzang NJ, et al. Pooled analysis of advanced renal cell carcinoma (RCC) patients (pts) treated with gemcitabine (G) and 5-fluorouracil (F). Proc Amer Soc Clin Oncol 21:191 a (abstract 762): 2002.

    Google Scholar 

  42. Wirth MR Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283–295, 1993.

    PubMed  CAS  Google Scholar 

  43. Neidhart JA, Anderson SA, Harris JE, et al.Vinblastine fails to improve response of enal cancer to interferon alfa-nl: high response rate in patients with pulmonary metastases. J Clin Oncol 9: 832–836,1991.

    PubMed  CAS  Google Scholar 

  44. Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265–269,1987.

    Article  PubMed  CAS  Google Scholar 

  45. Fojo AT, Shen DW, Mickley LA, et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 5: 1922–1927,1987.

    PubMed  CAS  Google Scholar 

  46. Duensing S, Dal mann I, Grosse J, et al. Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology 51: 309–313,1994.

    Article  PubMed  CAS  Google Scholar 

  47. Mickisch GH, Roehrich K, Koessig J, et al. Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J Urol 144: 755–759,1990.

    PubMed  CAS  Google Scholar 

  48. Samuels BL, Hollis DR, Rosner GL, et al. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin Cancer Res 3: 1977–1984,1997.

    PubMed  CAS  Google Scholar 

  49. Warner E, Tobe SW, Andrulis IL, et al. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Am J Clin Oncol 18: 251–256,1995.

    Article  PubMed  CAS  Google Scholar 

  50. Schwartsmann G, Medina de Cunha F, Silveira LA, et al. Phase II trial of vinblastine plus nifedipine (VN) in patients with advanced renal cell carcinoma (RCC). Brazilian Oncology Trials Group. Ann Oncol 2: 443,1991.

    PubMed  CAS  Google Scholar 

  51. Murphy BR, Rynard SM, Pennington KL, et al. A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study. Am J Clin Oncol 17: 10–13, 1994.

    Article  PubMed  CAS  Google Scholar 

  52. Motzer RJ, Lyn P, Fischer P, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 13: 1958–1965,1995.

    PubMed  CAS  Google Scholar 

  53. Agarwala SS, Bahnson RR, Wilson JW, et al. Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma. A phase I study. Am J Clin Oncol 18: 211–215,1995.

    Article  PubMed  CAS  Google Scholar 

  54. Chico I, Kang MH, Bergan R, et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol 19: 832–842,2001.

    PubMed  CAS  Google Scholar 

  55. Yang JC, Haworth L, Steinberg SM, et al. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc Amer Soc Clin Oncol 21:19a (abstract 15): 2002.

    Google Scholar 

  56. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20: 2376–2381,2002.

    Article  PubMed  Google Scholar 

  57. Eisen T Thalidomide in solid malignancies. J Clin Oncol 20: 2607–2609,2002.

    PubMed  Google Scholar 

  58. Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 58: 808–814, 1998.

    PubMed  CAS  Google Scholar 

  59. Atkins MB, Hidalgo M, Stadler W, et al. A randomized double-blinded phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc Amer Soc Clin Oncol 21:10a (abstract 36): 2002.

    Google Scholar 

  60. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98: 10314–10319, 2001.

    Article  PubMed  CAS  Google Scholar 

  61. Kondo K, Yao M, Kobayashi K, et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 91: 219–224, 2001.

    Article  PubMed  CAS  Google Scholar 

  62. Stadler WM, Ratain MJ. Development of target-based antineoplastic agents. Invest New Drugs 18: 7–16, 2000.

    Article  PubMed  CAS  Google Scholar 

  63. Venner P, Eisenhauer EA, Wierzbicki R, et al. Phase II study of 2’-deoxycoformycin in patients with renal cell carcinoma. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 9: 273–275, 1991.

    Article  PubMed  CAS  Google Scholar 

  64. Witte RS, Walsh C, Fisher H, et al Evaluation of deoxycoformycin in patients with advanced renal cell carcinoma. An ECOG pilot study. Invest New Drugs 10: 49–50, 1992.

    Article  PubMed  CAS  Google Scholar 

  65. Zaniboni A, Simoncini E, Marpicati P, et al. Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer. J Chemother 1: 350–351, 1989.

    PubMed  CAS  Google Scholar 

  66. Schulof R, Lokich j,Wampler G, et al. Phase II trial of protracted infusional 5-FU (PIF) for metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 10: 170, 1991.

    Google Scholar 

  67. Ahlgren JD, Lokich J, Auerbach M, et al. Protracted infusional 5FU (PIF): a well tolerated regimen in metastatic renal cell carcinoma (MRC): A Mid-Atlantic Oncology Program (MOAP) study. Proc Am Soc Clin Oncol 12: 244, 1993.

    Google Scholar 

  68. Johnson DE, Chalbaud RA, Holoye PY, et al. Clinical trial of bleomycin (NSC-125066) in the treatment of metastatic renal carcinoma. Cancer Chemother Rep 59: 433–435, 1975.

    PubMed  CAS  Google Scholar 

  69. Haas CD, Coltman CA, Jr, Gottlieb JA, et al. Phase II evaluation of bleomycin. A Southwest oncology Group study. Cancer 38: 8–12, 1976.

    Article  PubMed  CAS  Google Scholar 

  70. Hahn DM, Schimpff SC, Ruckdeschel JC, et al. Single-agent therapy for renal cell carcinoma: CCNU, vinblastine, thioTEPA, or bleomycin. Cancer Treat Rep 61: 1585–1587, 1977.

    PubMed  CAS  Google Scholar 

  71. Tait M, Abrams J, Egorin MJ, et al. Phase II carboplatin (CBDCA) for metastatic renal cell cancer with a standard dose (SD) and a calculated dose (CD) according to renal function. Proc Am Soc Clin Oncol 7: 125, 1988.

    Google Scholar 

  72. Trump DL, Elson P. Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma. Invest New Drugs 8: 201–203, 1990.

    PubMed  CAS  Google Scholar 

  73. Rodriguez LH, Johnson DE. Clinical trial of cisplatinum (NSC 119875) in metastatic renal cell carcinoma. Urology 11: 344–346, 1978.

    Article  PubMed  CAS  Google Scholar 

  74. Merrin CE. Treatment of genitourinary tumours with cis-dichlorodiammineplatinum(II): experience in 250 patients. Cancer Treat Rep 63: 1579–1584, 1979.

    PubMed  CAS  Google Scholar 

  75. Kiruluta G, Morales A, Lott S. Response of renal adenocarcinoma to cyclophosphamide. Urology 6: 557–558, 1975.

    Article  PubMed  CAS  Google Scholar 

  76. Hahn RG, Bauer M, Wolter J, et al. Phase II study of single-agent therapy with megestrol acetate, VP-16–213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer. Cancer Treat Rep 63: 513–515, 1979.

    PubMed  CAS  Google Scholar 

  77. Wajsman Z, Beckley S, Madajewicz S. High dose cyclophosphamide in metastatic renal cell cancer. Proc Am Soc Clin Oncol 21: 423, 1980.

    Google Scholar 

  78. Hahn RG, Begg CB, Davis T. Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer. Cancer Treat Rep 65: 711–713, 1981.

    PubMed  CAS  Google Scholar 

  79. Mertens WC, Eisenhauer EA, Jolivet J, et al. Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5: 185–187, 1994.

    PubMed  CAS  Google Scholar 

  80. O’Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 39: 1940–1948, 1977.

    Article  PubMed  Google Scholar 

  81. Fossa SD, Wik B, Bae E, et al. Phase II study of 4’-epi-doxorubicin in metastatic renal cancer. Cancer Treat Rep 66: 1219–1221, 1982.

    PubMed  CAS  Google Scholar 

  82. Benedetto P, Ahmed T, Needles B, et al. Phase II trial of 4’epi-adriamycin for advanced hypernephroma. Am J Clin Oncol 6: 553–554, 1983.

    PubMed  CAS  Google Scholar 

  83. Swanson DA, Johnson DE. Estramustine phosphate (Emcyt) as treatment for metastatic renal carcinoma. Urology 17: 344–346, 1981.

    Article  PubMed  CAS  Google Scholar 

  84. Balducci L, Blumenstein B, Von Hoff DD, et al. Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study. Cancer Treat Rep 71: 543–544,1987.

    PubMed  CAS  Google Scholar 

  85. Shevrin DH, Lad TE, Kilton Lj, et al. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study. Invest New Drugs 7: 251–253,1989.

    Article  PubMed  CAS  Google Scholar 

  86. Rohde D, De Mulder PH, Weissbach L, et al. Experimental and clinical efficacy of 2’,2’- difluorodeoxycytidine (gemcitabine) against renal cell carcinoma. Oncology 53: 476–481,1996.

    Article  PubMed  CAS  Google Scholar 

  87. Stolbach LL, Begg CB, Hall T, et al. Treatment of renal carcinoma: a phase III randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine. Cancer Treat Rep 65: 689–692, 1981.

    PubMed  CAS  Google Scholar 

  88. Fossa SD, Talle K. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation. Cancer Treat Rep 64: 1103–1108,1980.

    PubMed  CAS  Google Scholar 

  89. Heim ME, Fiene R, Schick E, et al. Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma. J Cancer Res Clin Oncol 100: 113–116,1981.

    Article  PubMed  CAS  Google Scholar 

  90. De Forges A, Droz JP, Ghosn M, et al. Phase II trial of ifosfamide/mesna in metastatic adult renal carcinoma. Cancer Treat Rep 71: 1103,1987.

    PubMed  Google Scholar 

  91. Bodrogi I, Bald M, Sinkovics I, et al. Ifosfamide chemotherapy of metastatic renal cell cancer. Semin Surg Oncol 4: 95–96,1988.

    PubMed  CAS  Google Scholar 

  92. Law TM, Mencel P, Motzer RJ. Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest New Drugs 12: 323–325,1994.

    Article  PubMed  CAS  Google Scholar 

  93. Falkson CI. New formulation intravenous melphalan in the treatment of patients with metastatic renal cancer. Invest New Drugs 11: 93,1993.

    Article  PubMed  CAS  Google Scholar 

  94. Baumgartner G, Heinz R, Arbes H, et al. Methotrexate-citrovorum factor used alone and in combination chemotherapy for advanced hypernephromas. Cancer Treat Rep 64: 41–46,1980.

    PubMed  CAS  Google Scholar 

  95. Stewart DJ, Futter N, Irvine A, et al. Mitomycin-C and metronidazole in the treatment of advanced renal-cell carcinoma. Am J Clin Oncol 10: 520–522,1987.

    Article  PubMed  CAS  Google Scholar 

  96. Hogan TF, Citrin DL, Freeberg BL. A preliminary report of mitotane therapy of advanced renal and prostate cancer. Cancer Treat Rep 65: 539–540,1981.

    PubMed  CAS  Google Scholar 

  97. De Jager R, Cappelaere P, Armand JP, et al. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. Eur J Cancer Clin Oncol 20: 1369–1375,1984.

    Article  PubMed  Google Scholar 

  98. Taylor SA, Von Hoff DD, Baker LH, et al. Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. Cancer Treat Rep 68: 919–920, 1984.

    PubMed  CAS  Google Scholar 

  99. van Oosterom AT, Fossa SD, Pizzocaro G, et al. Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur J Cancer Clin Oncol 20: 1239–1241,1984.

    Article  PubMed  Google Scholar 

  100. Gams RA, Nelson 0, Birch R. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 70: 921–922,1986.

    PubMed  CAS  Google Scholar 

  101. Natale RB, Yagoda A, Kelsen DP, et al. Phase II trial of PALA in hypernephroma and urinary bladder cancer. Cancer Treat Rep 66: 2091–2092,1982.

    PubMed  CAS  Google Scholar 

  102. Einzig AI, Gorowski E, Sasloff I et al. Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest 9: 133–136,1991.

    Article  PubMed  CAS  Google Scholar 

  103. La Rocca RV, Stein CA, Danesi R, et al. A pilot study of suramin in the treatment of metastatic renal cell carcinoma. Cancer 67: 1509–1513,1991.

    Article  PubMed  Google Scholar 

  104. Motzer RJ, Nanus DM, O’Moore P, et al. Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res 52: 5775–5779,1992.

    PubMed  CAS  Google Scholar 

  105. Park DK, Ryan CW, Dodlan ME, et al. A phase II trial of temozolomide in patients with metastatic renal cell cancer. Cancer Chem Pharm: (in press).

    Google Scholar 

  106. Law TM, Ilson DH, Motzer RJ. Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 12: 143–145,1994.

    Article  PubMed  CAS  Google Scholar 

  107. Wong PP, Yagoda A, Currie VE, et al. Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma. Cancer Treat Rep 61: 1727–1729,1977.

    PubMed  CAS  Google Scholar 

  108. Fossa SD, Denis L, van Oosterom AT, et al. Vindesine in advanced renal cancer. A study of the EORTC Genito-urinary Tract Cancer Cooperative Group. Eur J Cancer Clin Oncol 19: 473–475, 1983.

    Article  PubMed  CAS  Google Scholar 

  109. Canobbio L, Boccardo F, Guarneri D, et al. Phase II study of navelbine in advanced renal cell carcinoma. Eur J Cancer 27: 804–805,1991.

    PubMed  CAS  Google Scholar 

  110. Wilding G, Kirkwood J, Clamon G, et al. Phase II trial of navelbine in metastatic renal cancer. Proc Am Soc Clin Oncol 12: 253,1993.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Associate, Section of ematology/Oncology, University of Chicago Medical Center, 5841 South Maryland Ave, MC 2115, 60637-1470, Chicago, IL, USA

    Christopher M. George M.D.

  2. Associate Professor, Sections of Hematology/Oncology and Urology, Departments of Medicine and Surgery, University of Chicago Medical Center, 5841 South Maryland Ave, 60637-1470, Chicago, IL, USA

    Walter M. Stadler M.D.,F.A.C.P.

Authors
  1. Christopher M. George M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Walter M. Stadler M.D.,F.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of California, Los Angeles, CA, USA

    Robert A. Figlin

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

George, C.M., Stadler, W.M. (2003). The Role of Systemic Chemotherapy in the Treatment of Kidney Cancer. In: Figlin, R.A. (eds) Kidney Cancer. Cancer Treatment and Research, vol 116. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0451-1_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0451-1_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5083-5

  • Online ISBN: 978-1-4615-0451-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation